** Canadian drug developer’s U.S.-listed shares up 22 pct at $3.88 premarket
** Second-top pct gainer among Nasdaq-listed stocks
** Co announces global license deal with privately held OHM Oncology for development and commercialization of cancer drug, APL-581, as well as related molecules and kinase inhibitor program
** Aptose will retain reacquisition rights to certain molecules, while OHM will have the rights to develop and sublicense all other molecules
** Under this deal, Aptose will receive a nominal upfront cash payment and is eligible to receive up to $125 mln of additional payments based on the achievement of certain development, regulatory and sales milestones, as well as significant royalties
** APTO up ~42 pct this year (Reporting by Akankshita Mukhopadhyay in Bengaluru)
